Targeting deubiquitinating enzyme USP26 by microRNA-203 regulates Snail1’s pro-metastatic functions in esophageal cancer

Gang Li¹, Hong-wei Qi², He-gui Dong³, Ping Bai¹, Ming Sun¹ and Hai-yan Liu⁴*

Abstract

Background: Esophageal cancer is one of the most common cancers worldwide with poor prognosis and high mortality. The transcription factor SNAI1, encoding Snail1, is important for metastatic progression in esophageal cancer whereas the microRNA (miRNA)-203 has been shown to function as an inhibitor of metastasis in EC. The Snail1 protein is stabilized in EC partially by the deubiquitinating enzyme USP26; however, how USP26 is regulated is not completely known.

Methods: Expression of SNAI1 and USP26 messenger RNA (mRNA) and miR-203 was performed in datasets within The Cancer Genome Atlas and Gene Expression Omnibus, respectively. Expression of Snail1 and USP26 protein and miR-203 was determined in the normal esophageal cell line HET-1A and EC cell lines Kyse150 and TE-1 using western blot and quantitative polymerase chain reaction, respectively. TargetScan was used for in situ prediction of miR-203 targets and in vitro heterologous reporter assays using the wild-type and miR-203 seed mutant of the 3′ Untranslated region (UTR) of USP26 were used to investigate whether USP26 is a target of miR-203. Effects of increasing miR-203 using MIR203A/5P mimic on USP26 and Snail1 in the HET-1A, Kyse150 and TE-1 cell lines were performed using western blot and cycloheximide-based protein stability analysis. Effects of modulating miR-203 in Kyse150 and TE-1 cell lines on in vitro pro-metastatic effects were analyzed by invasion assay, scratch wound-healing assay, and chemosensitivity to 5-fluorouracil (5-FU). In vivo lung metastasis assay was used to study the effect of modulating miR-203 in Kyse150 cells.

Results: SNAI1 mRNA and HSA/MIR203 was higher and lower, respectively, in EC patients compared to tumor-adjacent normal tissues. No changes in expression of USP26 mRNA were observed in these datasets. MIR/203 expression was downregulated whereas protein expression of both Snail1 and USP26 were higher in EC cell lines Kyse150 and TE-1 compared to normal esophageal cell line HET-1A. USP26 was predicted as a potential target of miR-203 by TargetScan Release 2.0. Reporter assays confirmed USP26 as a target of miR-203 in the EC cell lines. Transfection of EC cell lines with MIR203 mimic decreased USP26 protein expression and Snail1 protein stability indicating the ability of miR-203 to regulate Snail1 protein levels via USP26. Exogenous increase in miR-203 in the EC cell lines significantly inhibited Snail-1 mediated in vitro pro-metastatic function of invasion, wound-healing, and increased chemosensitivity to 5-FU. Finally, overexpression of miR-203 inhibited in vivo lung metastasis of Kyse150 cells, which was reversed...
Background

Esophageal cancer (EC) is the sixth-most common cancer worldwide with high incidence of metastasis detection at initial diagnosis [1–4] and a poor 5-year survival period of 15–25% [5, 6]. Indeed, cancer metastasis is the prime reason for all cancer related mortality, accounting for approximately 90% of deaths associated with cancer [1].

One of the important initiating steps of cancer metastasis is epithelial to mesenchymal transition (EMT), whereby epithelial cancer cells within a primary tumor acquire morphological, phenotypical, and functional changes that aid them to migrate to secondary sites [7]. EMT is also critically important in rendering chemoresistance to cancer cells [7]. Given the importance of EMT in cancer progression it is not surprising that the process is regulated by multiple mechanisms at different transcriptional, post-transcriptional and post-translational stages.

One of the most important and well-characterized transcription factors required for EMT progression is SNAI1, which encodes Snail1. Expression of Snail1 was found to be positively correlated to metastatic progression in EC patients [8, 9]. Snail1 protein is post-translationally regulated by the ubiquitin-proteasome system, with SPSB3, FBXO11, FBXL14 and β-TrCP functioning as the cognate E3 ligases in a context-dependent fashion [10–13]. These actions of E3 ligases have been shown to be regulated among others by deubiquitinating enzymes (DUBs), including DUB3, OTUB1, PSMD14, and USP26 [14–18]. USP26-mediated regulation of Snail1 stabilization has been shown to potentiate metastatic progression in EC [18]. However, how expression of USP26 is regulated is not currently known.

Much like the protein effectors of EMT and metastatic progression, several microRNAs (miRNAs) have been indicated to be critical in EMT and metastatic progression [19–23]. Among the different miRNAs that have been shown to regulate different steps of EC, there seems to be a consensus about the miR-203 functioning as an inhibitor of metastatic progression in EC [24] with its expression downregulated in EC. It has been reported that miR-203 inhibits EC progression by targeting the stem cell renewal factor Bmi-1 [25]. However, whether there are additional targets of miR-203 that potentiates its role in suppressing EC is not known.

In this study we confirm that miR-203 expression is significantly downregulated in both EC patients and cell lines compared to tumor-adjacent normal tissue and normal human esophageal squamous cell line, respectively. USP26 was found to be a putative target of miR-203 and was confirmed as a bona fide target by a combination of heterologous reporter assays and in vitro and in vivo functional studies. Our results also showed that exogenous modulation of USP26 expression in EC cell lines by miR-203 directly impact Snail1 protein stability and pro-metastatic in vitro functions of migration, invasion, and chemoresistance to 5-fluorouracil (5-FU), as well as in vivo metastasis. These results establish miR-203 as a potential biomarker as well as an attractive therapeutic target in EC.

Methods

Cell culture

The normal esophagus cell line HET-1A and EC cell lines, Kyse150 and TE-1 were purchased from ATCC (USA) and iCell Bioscience Inc., Shanghai, China, respectively. HET-1A was cultured in BEGM (BEBM along with additives except for the gentamycin-amphotericin B mix) (Lonza Clonoletics Corporation, USA). TE-1 and Kyse150 cells were cultured in 10% fetal bovine serum (Thermo Fisher Scientific, USA) containing RPMI1640 (Thermo Fisher Scientific) media. All cells were maintained in an incubator at 37 °C, saturated humidity, and 5% carbon dioxide. For Snail1 protein stability assays, cells were treated with cycloheximide (50 µg/ml; Sigma-Aldrich, USA) for up to 8 h.

Immunoblot analysis

At the end of experimental time points cells were washed with ice-cold 1X phosphate buffered saline and then lysed using RIPA buffer (Thermo Fisher Scientific). Protein concentrations were determined by BCA kit (Thermo Fisher Scientific). Fifty micrograms of protein lysates were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to PVDF membranes. Membranes were blotted using the following antibodies as indicated: SNAIL1 (clone 20C8,
1:500, Thermo Fisher Scientific), USP26 (catalogue # PA5-96893, 1:1000, Thermo Fisher Scientific), E-cadherin (catalogue # 3195, 1:1000; Cell Signaling Technologies, USA) and GAPDH (catalogue # MA5-15738, 1:5000, Thermo Fisher Scientific). GAPDH was used as a loading control. All immunoblot images are representative of 3 experiments.

Isolation of miRNA and quantitative real time polymerase chain reaction (qRT-PCR)

At the end of experimental time points cells were washed with ice-cold 1x phosphate buffered saline. Cell pellets were then used to isolate miRNA using PureLink miRNA isolation kit (Thermo Fisher Scientific). qRT-PCR was done using TaqMan probes (hsa-miR-203a-5p: assay ID-477013_mat and RNU6B: assay ID-001093; Thermo Fisher Scientific). Expression of miR-203a-5p was normalized to RNU6B expression and relative expression in HET-1A, Kyse150, and TE-1 cells lines were calculated using the 2^−ΔΔCt method. Data was presented as scattered dot plot (mean±standard deviation (SD)) of six biological replicates, each done in three technical replicates.

Bioinformatic analysis

cBioPortal (https://www.cbioportal.org/) was used to analyze the relative expression of SNAI1 and USP26 in 1687 patients. Non-coding RNA profiling array data were downloaded from GEO [26]—GSE. TargetScan Human release 2.0 was used to predict potential targets of miR-203a-5p and potential miRNAs binding 3’UTR of USP26. Our analysis revealed that USP26 3’UTR was found to harbor a 7mer-A8 seed for miR-203a-5p.

Plasmids, mimics, and transfection

The wild-type 3’UTR of USP26 was amplified from genomic DNA using forward primer 5’-ctcttgcttcagcttgcgtga-3’ and reverse primer 5’-tcacaaggcagcataca-3’ and cloned into pGL3 vector (Promega, USA). The miR-203a-5p seed mutant 3’UTR of USP26 (mutant 3’UTR) was generated by site directed mutagenesis using Quick Change II kit (Agilent, USA) and the following primers: 5’-tctgctcagcttgattcactgatacagtgc-3’ and 5’-gaccgtggtcttcagctttggagacaactctgtacta-3’. The miR-203a-5p (MIR203A/5P) and non-sense scrambled negative control (control) mimics were purchased from Thermo Fisher Scientific. For reporter assays, cells (4×10⁴) were plated in 24-well plates 24 h before transfection. Cells were transfected with 0.5 µg each of 3’UTR containing pGL3 vector and a control pSV40-RLL (encoding Renilla luciferase, internal control) using Lipofectamine 3000 (Thermo Fisher Scientific). Where indicated, cells were transfected with 30 nM of control or MIR203A/5P mimic using RNAiMAX reagent (Thermo Fisher Scientific) 24 h before transfection of the luciferase reporter plasmids. Reporter assays were performed 24 h after transfection using Dual Luciferase Assay kit (Promega). Firefly luciferase values were normalized using Renilla luciferase values from the same wells and then relative changes in reporter activities were calculated for each experimental setting. Data was plotted as scattered dot plot (median±range) of three biological replicates. For generating cells for xenograft assay, Kyse150 cells were transduced using lentivirus encoding Firefly luciferase and selected using G418 (500 µg/ml, Thermo Fisher Scientific) for 2 weeks. Firefly luciferase expressing Kyse150 cells were subsequently transduced with USP26 expressing lentivirus (#RC223359L1V, Origene) and selected using puromycin (2 µg/ml, Thermo Fisher Scientific) for 2 weeks.

Invasion assay

In vitro invasion assay was performed in 96-well format using Cultrex Basement Membrane Extract Cell Invasion Assay kit (catalog # 3455-096-K; R&D Systems, USA). Cells (5×10⁴) were serum starved for 12 h before adding to the top chambers, whereas complete medium was used as chemoattractant in all cases. Post-experiment bottom of wells was stained using crystal violet and imaged. Quantification was done by lysing and measuring fluorescent activity using Calcein AM as per manufacturer’s protocol. Absolute number of cells were calculated from standard curve using OD values obtained from Calcein AM assay. Data was plotted as scattered dot plot (median±range) of three biological replicates, each done in duplicate technical controls.

Migration–Scratch wound-healing assay

Twenty-four hours after transfection with control of MIR203A/5P mimic, TE-1 and Kyse150 cells were plated in six-well flat-bottom plates (Thermo Fisher Scientific) and allowed to grow to a confluent cell monolayer. Scratching was performed using a 200-μl sterile pipette tip. Subsequently, the wells were washed with 1× PBS to get rid of the floating cells. The cells were cultured in growth medium and imaged 24 h later. Migration was defined as percentage of wound closure after 24 h and calculated as: [(Original gap distance – Gap distance after 24 h) / (Original gap distance)] x 100.

Chemosensitivity assay

Kyse150 and TE-1 cells were transfected with control or MIR203A/5P mimic for 24 h as described above before being treated with indicated doses of 5-FU (Sigma-Aldrich) for 24 h. After treatment period, relative cell viability was quantified using MTT assay (Sigma-Aldrich).
as per manufacturer’s protocol. Data was plotted as staggered representation of each replicate.

**Mouse models of metastasis and tissue processing**

Institutional Animal Care and Use Committees of The Second Affiliate Hospital of Shandong First Medical University approved all animal studies conducted in the context of the current study. BALB/c nude mice were intravenously injected via lateral tail vein with parental Kyse50 cells stably expressing firefly luciferase (n = 10) or Kyse150 cells stably expressing firefly luciferase and USP26 (n = 05) (1 × 10^6 in 100 µl PBS). Twenty-four hours later mice injected with parental Kyse150 cells were randomly divided into 2 groups – control and MIR203A/5P mimic group. Mice in the control group were injected with 100 mg/kg control mimic every alternate day, whereas mice in the MIR203A/5P mimic group were injected with 100 mg/kg MIR203A/5P mimic every alternate day. Mice injected with Kyse150 cells over-expressing USP26 were also injected with 100 mg/kg MIR203A/5P mimic every alternate day. Bioluminescence imaging for firefly luciferase was used to track the experimental metastatic progression. Animals were euthanized in humane fashion after 6 weeks and lungs were excised and fixed overnight in 10% neutral buffered formalin. Tissue specimens were processed using routine procedures for H&E staining and evaluated for histological assessment of lung metastasis. Immunohistochemistry for USP26 was done using USP26 antibody (catalogue # PA5-96893, 1:50, Thermo Fisher Scientific) following manufacturer’s protocol.

**Statistical analysis**

All data were analyzed using GraphPad Prism V8. Statistical difference between groups was calculated using unpaired non-parametric Mann Whitney test. P < 0.05 was considered as statistically significant.

**Results**

**Differential regulation of SNAI1 and hsa-miR-203 in esophageal cancer patient samples**

It has been shown that SNAI1 expression is correlated to EC progression [9] and USP26 stabilizes Snail1 protein in EC [18]. Hence, we initially confirmed expression of SNAI1 and USP26 messenger RNA (mRNA) in EC patients. SNAI1 was upregulated 6.23 ± 3.11 folds in the Esophagus (TCGA PanCan) data set and 6.59 ± 3.02 folds in the Esophagus (TCGA) datasets, respectively (Fig. 1a). There was no significant change in expression of USP26 in the same datasets (Fig. 1b). We next analyzed miR-203 expression in GSE43732 and GSE6188. It is important to note that previous analysis of these 2 datasets by He et al. 2019 [24] had shown miR-203 as one of 17 differentially expressed miRNA between EC and tumor-adjacent normal tissue in patient samples. The goal of our re-analysis was to exclusively represent relative expression of miR-203 in EC tissue and tumor-adjacent normal tissue. Confirming the previous findings [24], in 119 paired patient samples in GSE43732, miR-203 expression was significantly downregulated in esophageal tumor tissue (Fig. 1c; P < 0.0001) and in 104 tumor-adjacent normal tissue and 153 esophageal tumor tissue patient samples in GSE6188, miR-203 expression was significantly downregulated in esophageal tumor tissue (Fig. 1d; P < 0.0001). Overall, these results validated that SNAI1 and miR-203 expressions are up and down regulated, respectively, in EC.

**Differential expression of Snail1 and USP26 protein and miR-203a-5p in normal esophagus and EC cell lines**

We next performed expression analysis in the normal esophagus cell line HET-1A and the EC cell lines Kyse150 and TE-1. Steady state protein expression of both Snail1 and USP26 were higher in the EC cell lines compared to the HET-1A cell line, where USP26 was hardly detected (Fig. 2a). Compared to HET-1A, expression of miR-203 was 10.31 ± 0.33 folds and 7.36 ± 0.88 folds downregulated in Kyse150 and TE-1 cells, respectively (Fig. 2b; P < 0.0001 in each case compared to HET-1A).

**USP26 is a target of miR-203 in esophageal cancer cell lines**

Given that USP26 mRNA was not changing between normal and tumor esophagus tissue but were increasing at the protein level, we hypothesized that USP26 is regulated by miRNA at the level of mRNA translation. We used TargetScan v2.0 to predict putative miRNAs targeting the 3’UTR of USP26. Given that miR-203a-5p was downregulated in EC, we also used TargetScan v2.0 to predict putative gene targets of miR-203a-5p. Both analyses revealed USP26 was a putative target of miR-203a-5p with USP26 harboring a 7merm8 seed for miR-203a-5p (Fig. 3a).

In order to confirm if USP26 is a real target of miR-203a-5p we generated firefly luciferase reporter plasmid harboring either the wild-type or miR-203a-5p seed mutant 3’UTR of USP26. Luciferase reporter assay showed that reporter activity of the wild-type 3’UTR USP26 was 10.24 ± 1.09 and 8.81 ± 1.11 folds compared to Kyse150 and TE-1 cells, respectively (Fig. 3b; P < 0.0001 in each case). This observation was in sync with significantly lower expression of miR-203A-5p in the Kyse150 and TE-1 cells compared to HET-1A cells (Fig. 2b). If indeed the difference in reporter activity was due to difference in expression of miR-203a-5p then mutating the binding site for miR-203a-5p in the reporters would attenuate the repression observed in the HET-1A cells. Indeed, when mutant reporters were used no
significant differences in reporter activity were observed in the HET-1A, Kyse150 and TE-1 cells (Fig. 2b). For further convincing evidence, all three cells were transfected with either a control or MIR203A/5P mimic. Successful transfection was verified by qRT-PCR (Fig. 3c). These cells were subsequently transfected with the wild type reporter constructs and relative reporter activity in the cells transfected with control or MIR203A/5P mimic were compared. Transfection of MIR203A/5P mimic significantly decreased reporter activity by 8.56 ± 1.61 (P < 0.01), 6.84 ± 1.17 (P < 0.0001), and 5.02 ± 0.26 (P < 0.001) folds in the HET-1A, Kyse150, and TE-1 cells, respectively (Fig. 3d). These results confirmed that USP26 is truly being targeted by miR-203a-5P in the normal esophageal cell line HET-1A and that it is derepressed in the EC cell lines TE-1 and Kyse150.

Modulating miR-203 expression in EC cell lines impact stability of Snail1 protein

If USP26 was indeed being targeted by miR-203a-5P, then it would result in downregulation of USP26 protein
expression and by extension destabilize Snail1 protein. To investigate that immunoblot analysis was performed in the HET-1A, Kyse150, and TE-1 cells transfected with control or MIR203A/5P mimic. The MIR203A/5P mimic caused a robust downregulation of both USP26 and Snail1 in both the Kyse150 and TE-1 cells (Fig. 4a). Given Snail1 function in EMT by downregulating the epithelial cell marker E-cadherin [9], we also determined expression of E-cadherin in the control or MIR203A/5P mimic-transfected HET-1A, Kyse150, and TE-1 cell lines. The MIR203A/5P mimic increased E-cadherin in both the Kyse150 and TE-1 cells (Fig. 4a).

To confirm that the change in Snail1 protein expression in the MIR203A/5P mimic-transfected cells was due to decrease in Snail1 stability caused by a decrease in USP26 protein, we performed protein stability analysis in TE-1 cells transfected with control or MIR203A/5P mimic. Cells were treated with the translation elongation inhibitor cycloheximide for up to 8 h and relative expression of Snail1 protein was determined by immunoblot analysis. As shown in Fig. 4b, Snail1 protein was lower at 0 h in the MIR203A/5P mimic transfected TE-1 cells compared to the control mimic transected cells. These blots also suggested that Snail1 protein was degrading faster in the MIR203A/5P mimic transfected TE-1 cells. The half-life of Snail1 protein was significantly lowered following MIR203A/5P mimic transfection in the TE-1 cells 1.75 ± 0.11 h compared to 7.23 ± 0.09 h in the control mimic transected cells (Fig. 4c; P > 0.0001). These results proved that the decrease in Snail1 protein following upregulation of miR-203a-5p upregulation is due to increased degradation of the Snail1 protein induced by a loss of USP26 protein expression.

Overexpression of miR-203 in EC cell lines inhibit in vitro pro-metastatic functions

Given that Snail1 has been shown to be involved in EMT and metastatic progression in EC by transcriptionally lowering the expression of epithelial cell marker E-cadherin [9], we next investigated the effect of increasing miR-203a-5p expression levels in Kyse150 and TE-1 cells on in vitro invasion and migration, two critical functional readouts of EMT [7]. Increase in miR-203a-5p expression in Kyse150 cells downregulated in vitro invasion (Fig. 5a, c; P = 0.001) and migration (Fig. 5b, c; P < 0.0001) by 22.14 ± 2.83 and 37.02 ± 2.39 folds, respectively.
Similar results were obtained in the TE-1 cells (invasion: $28.31 \pm 3.19$ folds, $P < 0.0001$; migration: $49.83 \pm 3.34$ folds, $P < 0.0001$) (Fig. 5a–c).

EMT is also characterized by increased chemoresistance of cancer cells as they metastasize to secondary sites. Hence, we next determined chemoresistance of control and MIR203A/5P mimic transfected Kyse150 and TE-1 cells to increasing concentration (0–50 µM) of 5-FU. The IC$_{50}$ of 5-FU decreased from 18.23±1.12 µM in control mimic to 4.01±1.34 µM in MIR203A/5P mimic transfected Kyse150 cells (Fig. 5d; $P = 0.001$). Similarly, in the TE-1 cells the IC$_{50}$ of 5-FU decreased from greater than 50 µM in control mimic to 5.11±0.04 µM in MIR203A/5P mimic transfected cells (Fig. 5d; $P < 0.0001$). Cumulatively, the results show that modulating miR-203a-5p expression in EC cells impact Snail1 protein stability by decreasing USP26, which in turn inhibits the pro-metastatic functions of Snail1 in these cells.

**Suppression of miR-203-mediated regulation of USP26 is required for metastatic progression of EC cells**

We next wanted to determine if the in vitro findings of miR-203-mediated regulation of USP26 and pro-metastatic functions will hold in in vivo mice models of metastasis. Mice injected with parental Kyse150 cells had widespread lung metastasis after 6 weeks, as evident by bioluminescence signal (Fig. 6a, left panel) and micrometastatic lung lesions (Fig. 6b, left panel). IHC staining of lung lesions also revealed robust staining for USP26 in these mice (Fig. 6c, left panel). However, when these mice were injected with MIR203A/5P mimic every alternate day, it significantly decreased lung metastasis (Fig. 6a, b, middle panels). IHC staining also revealed downregulation of USP26 expression in the lung (Fig. 6c, middle panel). Given that miR-203 has many targets, we next wanted to confirm that its regulation of USP26 is indeed important for metastasis of EC cells. Hence, Kyse150 cells were stably transduced with a lentivirus expressing USP26 and these cells were then injected via tail vein in the mice. The mice in these groups were also injected on alternate day with MIR203A/5P mimic. Overexpression of USP26 reversed the inhibition of lung metastasis by MIR203A/5P mimic (Fig. 6a, b, right panels). As expected, robust expression of USP26 was seen in the lung lesions (Fig. 6c, right panel) in these groups of mice. Taken together these results corroborated our in vitro results and confirmed that deregulation of miR-203-mediated downregulation of USP26 is important for metastatic progression of EC.

**Discussion**

Our study provides evidence that decreased expression of miR-203a-5p along with increased mRNA and protein expressions of Snail1 can be used as molecular markers of EC. Expression of USP26 protein, but not mRNA, is also increased in the context of EC cell lines. It remains to be determined if USP26 protein is also increased in EC patient samples. Our results also indicate the therapeutic potential of strategies to upregulate miR-203a-5p expression in EC cells. Obviously, USP26 is not the only target of miR-203a-5p. In the context of EC, miR-203a’s function has been to inhibit β-catenin signaling, cell migration and invasion via directly inhibiting KIF5C expression in turn potentiating the antitumor activities of the downstream protein, Axin2 [24].
Different targets of miR-203a have been defined in the context of other cancers, like *RAB22A* (encoding Ras-related protein Rab-22A) and *BIRC5* (encoding survivin) in osteosarcoma [27, 28]. Hence, gene expression analysis post-miR-203A-5p mimic transfection in EC cells and miR-203-5p inhibitor transfection in HET-1A cells along with genome wide reporter assays will be required to identify the whole spectrum of genes that are being targeted directly by miR-203 in the context of EC. Once identified, gene ontology and functional analysis can be performed to identify major targets. Such studies will lead to pre-clinical therapeutic studies where miR-203 expression or its downstream targets will function as novel candidates. MiR-203 functions as a tumor suppressor in different cancer types [29–36]. Hence, it also needs to be determined if the downstream targets of miR-203 are similar or context dependent in different cancer types.

The other important thing that needs to be investigated is what regulates miR-203 expression. It has been shown that in esophageal squamous cancer cells, epidermal growth factor-induced truncated CCAAT-enhancer-binding protein β (C/EBPβ) LIP isoform transcriptionally downregulates miR-203 expression by directly interacting with a conserved distal regulatory element upstream of the miR-203 locus [37].
Fig. 6 Suppression of miR-203-mediated regulation of USP26 is required for metastatic progression of EC cells. Xenograft model of experimental metastasis was established by lateral tail vein injection of parental Kyse150 cells or Kyse150 cells stably overexpressing USP26 into BALB/c nude mice (n = 10 and 5 mice, respectively). The mice injected with parental Kyse150 cells were randomly divided into two groups – control mimic (n = 05) (left panels), and MIR203A/5P mimic (n = 05) (middle panels), where the mice injected with Kyse150 cells overexpressing USP26 received MIR203A/5P mimic (right panels). The incidence of metastasis was measured by luciferin injection and bioluminescence imaging. Shown are representative animals from each group after 6 weeks (a). Mice were euthanized at the end of 6 weeks and the lungs from each group of experimental animals were surgically excised, fixed overnight in 10% buffered formalin. Representative images of hematoxylin and eosin (H and E) staining of the lungs are shown (b). Black arrows indicate micrometastasis. Scale bar, 100 µm. c Representative images of IHC staining for USP26 protein in each experimental group. Scale bar, 30 µm.
esophageal cancer cells, it has been shown that cisplatin-induced E2F1 transactivates miR-203 by directly binding to its promoter [38]. More clarity is needed as to the precise mechanisms that regulate miR-203 expression in EC cells.

Finally, it is not surprising that given the importance of Snail1 protein in metastatic progression, expression of Snail1 is regulated at different stages of gene expression. Even USP26 is one of many DUBs that seem to stabilize Snail1 [14–18]. It remains to be determined if all the DUBs are being targeted by miR-203. If not, then it is important to define why just targeting USP26 by ectopic increase in miR-203 is enough to destabilize Snail1 protein. One possibility is that the DUBs are regulated or function as a group and when one member goes missing the entire protective mechanism falls apart.

Conclusions
In summary, our study provides evidence that downregulation of miR-203 favors pro-metastatic behavior in EC cells by derepressing USP26 and stabilizing Snail1 protein. Our results add to the evidence highlighting miR-203 as an important biomarker of disease progression in EC and also highlight the potential of therapeutic benefits of upregulation of miR-203 in inhibiting or delaying metastatic progression in EC.

Abbreviations
EC: Esophageal cancer; miRNA: microRNA; EMT: Epithelial to mesenchymal transition; DUBs: deubiquitinating enzymes; 5-FU: 5-fluorouracil.

Acknowledgements
Not applicable.

Authors’ contributions
GL and HYL designed the experiments; HWQ and HGD analyzed data; PB and MS carried out the experiments. GL prepared the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Surgical Oncology, Taian City Central Hospital, Taian 271000, Shandong, China. 2 Department of Medicine, Taian City Central Hospital, Taian 271000, Shandong, China. 3 Department of Outpatient, Taian City Central Hospital, Taian 271000, Shandong, China. 4 Department of Oncology, The Second Affiliate Hospital of Shandong First Medical University, No.706, Taishan Street, Taian 271000, Shandong, China.

Received: 7 May 2020 Revised: 15 July 2020 Accepted: 20 July 2020 Published online: 30 July 2020

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
2. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.
3. Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, et al. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980–2011) and predictions to 2015. Ann Oncol. 2014;25(1):283–90.
4. Visser E, Franken IA, Brosens LA, Ruurda JP, van Hillegeberg RL. Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget. 2017;8(3):5566–77.
5. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–509.
6. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.
7. Pastushenko I, Blanpain C. EMT Transition States during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
8. Pang L, Li Q, Li S, He J, Cao W, Lan J, et al. Membrane type 1-matrix metalloproteinase induces epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: observations from clinical and in vitro analyses. Sci Rep. 2016;6:22179.
9. Usami Y, Satake S, Nakayama F, Matsumoto M, Ohnuma K, Komori T, et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol. 2008;215(3):330–9.
10. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6(10):931–40.
11. Vinas-Castells R, Beltran M, Valls G, Gomez I, Garcia JM, Montserrat-Senistells B, et al. The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. J Biol Chem. 2010;285(37):3794–805.
12. Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA, et al. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell. 2014;26(3):358–73.
13. Liu Y, Zhou H, Zhu R, Ding F, Li Y, Cao X, et al. SP53B targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis. Oncogene. 2018;37(6):768–76.
14. Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923.
15. Wu Y, Wang Y, Lin Y, Liu Y, Wang Y, Jia J, et al. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun. 2017;8:14228.
16. Zhu R, Liu Y, Zhou H, Li L, Li Y, Ding F, et al. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma. Cancer Lett. 2018;418:125–34.
17. Zhou H, Liu Y, Zhu R, Ding F, Cao X, Lin D, et al. OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability. Oncogene. 2018;37(25):3356–68.
18. Li L, Zhou H, Zhu R, Liu Z. USP26 promotes esophageal squamous cell carcinoma metastasis through stabilizing Snail. Cancer Lett. 2019;448:52–60.
19. Skrzypek K, Majka M. Interplay among SNAIL1 transcription factor, microRNAs, long non-coding RNAs, and circular RNAs in the regulation of tumor growth and metastasis. Cancers. 2020;12:1.
20. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68(1):26–33.
21. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47(4):277–86.
22. Fu W, Pang L, Chen Y, Yang L, Zhu J, Wei Y. The microRNAs as prognostic biomarkers for survival in esophageal cancer: a meta-analysis. Sci World J. 2014;2014:523979.
23. Chen Z, Li J, Tian L, Zhou C, Gao Y, Zhou F, et al. MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma. Cancer Lett. 2014;350(1–2):34–42.
24. He R, Wang J, Ye K, Du J, Chen J, Liu W. Reduced miR-203 predicts metastasis and poor survival in esophageal carcinoma. Aging. 2019;11(24):12114–30.
25. Yu X, Jiang X, Li H, Guo L, Jiang W, Lu SH. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev. 2014;23(6):576–85.
26. Clough E, Barrett T. The Gene Expression Omnibus Database. Methods in molecular biology. Nucleic Acids Res. 2016;1418:93–110.
27. Yang D, Liu G, Wang K. miR-203 Acts as a Tumor Suppressor Gene in Osteosarcoma by Regulating RAB22A. PLoS ONE. 2015;10(9):e0132225.
28. Chen X, Chen XG, Hu X, Song T, Ou X, Zhang C, et al. MiR-34a and miR-203 Inhibit Survivin Expression to Control Cell Proliferation and Survival in Human Osteosarcoma Cells. J Cancer. 2016;7(9):1057–65.
29. Sheng J, Zhang J, Xiao M, Yang J, Zhang N. miR-203 Suppresses Bladder Cancer Cell Growth and Targets Twist1. Oncol Res. 2018;26(8):1155–65.
30. Zhou P, Jiang X, Zhang GX, Sun Q. MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM. Acta Biochim Biophys Sin. 2016;48(6):696–703.
31. Muhammad N, Bhattacharya S, Steele R, Ray RB. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 2016;7(36):58509–605.
32. Hu H, Xu Z, Li C, Xu C, Lei Z, Zhang HT, et al. MiR-145 and miR-203 represses TGF-beta-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells. Lung Cancer. 2016;97:87–94.
33. Xu M, Gu M, Zhang K, Zhou J, Wang Z, Da J. miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagn Pathol. 2015;10:24.
34. Li Z, Du L, Dong Z, Yang Y, Zhang X, Wang L, et al. MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity. PLoS ONE. 2015;10(1):e0116710.
35. Li J, Chen Y, Zhao J, Kong F, Zhang Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011;304(1):52–9.
36. Fu Q, Zhang J, Xu X, Qian F, Feng K, Ma J. miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRCS. Tumour Biol. 2016. https://doi.org/10.1007/s13277-016-5438-7.
37. Li J, Shan F, Xiong G, Chen X, Guan X, Wang JM, et al. EGF-induced C/EBPbeta participates in EMT by decreasing the expression of miR-203 in esophageal squamous cell carcinoma cells. J Cell Sci. 2014;127(Pt 17):3735–44.
38. Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu L, et al. miR-203 is a direct transcriptional target of EZF1 and causes G1 arrest in esophageal cancer cells. J Cell Physiol. 2015;230(4):903–10.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.